Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2029

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)

This is dose level 0 (de-escalation).

BIOLOGICAL

BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)

This is dose level 1, the starting dose.

BIOLOGICAL

BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)

This is dose level 2.

BIOLOGICAL

BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)

This is dose level 3.

BIOLOGICAL

Maximum tolerated dose

The maximum tolerated dose is yet to be determined.

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER